Concepedia

Sudipta Mahajan

SM

Statistics

Publications

16

Citations

1.1K

H-Index

14

Active since

1997

Affiliations

Vertex Pharmaceuticals (United States)(Current)

Dana-Farber Cancer Institute

Harvard University

Emory University

Brigham and Women's Hospital

Sudipta Mahajan is an author at Vertex Pharmaceuticals (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

1997–2020

16

Publications

16

Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling

David A. Frank, Sudipta Mahajan, Jerome Ritz · Nature Medicine · 1999 · 282 citations

, , +8

B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues.

David A. Frank, Sudipta Mahajan, Jerome Ritz · Journal of Clinical Investigation · 1997 · 244 citations · Full text

, , +18

Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune Diseases

Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock et al. · Journal of Medicinal Chemistry · 2015 · 87 citations

, , +16

Altered Interleukin-12 Responsiveness in Th1 and Th2 Cells Is Associated With the Differential Activation of STAT5 and STAT1

Jared Gollob, Erin A. Murphy, Sudipta Mahajan et al. · Blood · 1998 · 78 citations · Full text

VX-509 (Decernotinib) Is a Potent and Selective Janus Kinase 3 Inhibitor That Attenuates Inflammation in Animal Models of Autoimmune Disease

Sudipta Mahajan, James K. Hogan, Dina Shlyakhter et al. · Journal of Pharmacology and Experimental Therapeutics · 2015 · 60 citations

Rows per page

1–5 of 16